DGAP-News

Asahi Kasei Pharma selects Evotec as its partner for ion channel drug discovery

DGAP-News: Evotec AG / Key word(s): Alliance
Asahi Kasei Pharma selects Evotec as its partner for ion channel drug
discovery

26.03.2015 / 07:30

---------------------------------------------------------------------

Hamburg, Germany - 26 March 2015: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX, ISIN: DE0005664809) today announced it has entered into a
multi-target screening collaboration on several ion channel targets, with
Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei
Corporation, Tokyo, Japan.

Under the terms of the agreement, Evotec will use its world-class ion
channel platform to identify inhibitors of multiple ion channel targets.

Dr Mario Polywka, Chief Operating Officer of Evotec, stated: "We are
extremely pleased that Asahi Kasei Pharma has decided to undertake these
projects with Evotec. Our expertise and platform on ion channel drug
discovery has proven to add significant value to our partner's programmes
and we look forward to supporting Asahi Kasei Pharma in their own ion
channel drug discovery efforts."

Financial terms were not disclosed.


ABOUT ASAHI KASEI
The Asahi Kasei Group is a diversified group of companies led by holding
company Asahi Kasei Corp., with operations in the chemicals and fibers,
homes and construction materials, electronics, and health care business
sectors. Its health care operations include devices and systems for acute
critical care, dialysis, therapeutic apheresis, transfusion, and
manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic
reagents, and nutritional products. With more than 29,000 employees around
the world, the Asahi Kasei Group serves customers in more than 100
countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.

ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain, metabolic
diseases as well as oncology, inflammation and infectious diseases. Evotec